Journals / ANKEM Dergisi / 2012 / Cilt: 26 - Sayı: 1

Resistance of Burkholderia cepacia strains ısolated from intensive care unit to various antibiotics

Yoğun bakım ünitesinden izole edilen Burkholderia cepacia suşlarının çeşitli antibiyotiklere direnci

Pages
16–19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, because of the limited number of antibiotics recommended by CLSI, B.cepacia infections should be carefully evaluated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Burkholderia cepacia is an important pathogen that particularly causes fatal infections in intensive care units.
📊
Key Findings & Data:In this study, we aimed to determine the resistance rates to various antibiotics of B.cepacia strains isolated in intensive care unit of our hospital.
💡
Conclusion & Impact:However, because of the limited number of antibiotics recommended by CLSI, B.cepacia infections should be carefully evaluated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Yoğun bakım üniteleri · Anti-bakteriyel ajanlar · İlaç direnci

Abstract

Burkholderia cepacia is an important pathogen that particularly causes fatal infections in intensive care units. In this study, we aimed to determine the resistance rates to various antibiotics of B.cepacia strains isolated in intensive care unit of our hospital. Forty-three B.cepacia strains isolated from various clinical specimens sent from intensive care unit were included in the study. After microorganisms had been identified as non-fermentative by conventional methods, BD Phoenix automated mic- robiology system (Becton Dickinson, USA) was utilized for species level identification and for antibiotic susceptibility tests. The distribution of isolated 43 B.cepacia strains according to the sample types was determined as 23 from blood, 12 from urine, 4 from tracheal aspirate, 4 from other specimens (wound, catheter). Resistance rates for antibiotics were as follows: 5 % for meropenem, 7 % for levofloxacin, 7 % for trimetoprime-sulfamethoxazole, 9 % for ceftazidime and 32 % for chlorampheni- col. As a result, obtained resistance rates for B.cepacia which is associated with high mortality in intensive care units, were found lower compared to the other studies. However, because of the limited number of antibiotics recommended by CLSI, B.cepacia infections should be carefully evaluated.

Özet

Burkholderia cepacia, özellikle yoğun bakım ünitelerinde ölümcül infeksiyonlara neden olan önemli bir patojendir. Çalışmada, hastanemiz yoğun bakım ünitesinden izole edilen B.cepacia suşlarının çeşitli antibiyotiklere karşı direnç oranları- nın belirlenmesi amaçlanmıştır. Yoğun bakım ünitelerinden gönderilen çeşitli klinik örneklerden izole edilen 43 B.cepacia suşu konvansiyonel yöntem- lerle idantifiye edilmiş, tür düzeyinde tiplendirme ve antibiyotik duyarlılıkları için BD Phoenix otomatize mikrobiyoloji siste- minden (Becton Dickinson, ABD) yararlanılmıştır. Suşların izole edildiği örnek türüne göre dağılımı; 23 kan, 12 idrar, 4 trakeal aspirat, 4 diğer (yara, kateter) olarak tespit edilmiştir. Antibiyotiklere direnç oranları ise meropeneme % 5, levofloksa- sine % 7, trimetoprim-sulfametoksazole % 7, seftazidime % 9 ve kloramfenikole % 32 olarak bulunmuştur. Sonuç olarak, yoğun bakım ünitelerinde yüksek mortalite nedeni olan B.cepacia suşları için elde ettiğimiz direnç oran- ları, yapılan diğer çalışmalarla kıyaslandığında daha düşük bulunmuştur. Ancak CLSI’nin önerdiği antibiyotik sayısının kısıtlı olması nedeniyle B.cepacia infeksiyonları dikkatle değerlendirilmelidir.

🔖

Cite This Article

PARLAK, M., ÇIKMAN, A., GÜDÜCÜOĞLU, H., BERKTAŞ, M., BEKTAŞ, A. (2012). Resistance of Burkholderia cepacia strains ısolated from intensive care unit to various antibiotics. ANKEM Dergisi, Cilt: 26 - Sayı: 1, 16–19. https://ajindex.com/articles/157486

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidi me in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isola tes from patients with cystic fibrosis, Antimicrob Agents Chemother 1999;43(2):213-7. PMid:9925508 PMCid:89053 2. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement, M100-S20, CLSI, Wayne PA (2010). 3. Dizbay M, Tunccan OG, Sezer BE, Aktas F, Arman D. Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveil lance, J Infect Dev Ctries 2009;3(4):273-7. PMid:19759490 4. Enoch DA, Birkett CI, Ludlam HA. Non-fermen tative Gram-negative bacteria, Int J Antimicrob Agents 2007;29(3):33-41. http://dx.doi.org/10.1016/S0924-8579(07)72176-3 5. Gales AC, Jones RN, Andrade SS, Sader HS. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002), Mem Inst Oswaldo Cruz 2005;100(6):571-7. http://dx.doi.org/10.1590/S0074-02762005000 600011 6. Hancock RE. Resistance mechanisms in Pseudo monas aeruginosa and other nonfermentative gram-negative bacteria, Clin Infect Dis 1998; 27(1): 93-9. http://dx.doi.org/10.1086/514909 PMid:9710677 7. Hutchinson GR, Parker S, Pryor JA et al. Home use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fib rosis, J Clin Microbiol 1996;34(3):584-7. PMid:8904419 PMCid:228851 8. Lipowski D, Rzadkiewicz E, Czekalska-Lachowicz E. Burkholderia cepacia: a new pathogen causing nosocomial infections, Przegl Epidemiol 2008; 62(1):7-17. PMid:18536220 9. LiPuma JJ, Currie BJ, Lum GD, Vandamme PAR (Çeviren: G.Emektaş). Burkholderia, Stenotropho monas, Ralstonia, Cupriavidus, Pandoraea, Bre vundimonas, Comamonas, Delftia ve Acidovorax, “Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (eds) (Çeviri ed: A.Başustaoğlu). Klinik Mikrobiyoloji, 9.baskı” kitabında s.749-69,
  2. Atlas Kitapçılık, Ankara (2009). 10. Loutet SA, Valvano MA. A decade of Burkholderia cenocepacia virulence determinant research, Infect Immun 2010;78(10):4088-100. http://dx.doi.org/10.1128/IAI.00212-10 PMid:20643851 PMCid:2950345 11. McClean S, Callaghan M. Burkholderia cepacia complex: epithelial